Bruker Corporation $BRKR Shares Acquired by Fifth Third Bancorp

Fifth Third Bancorp increased its holdings in Bruker Corporation (NASDAQ:BRKR) by 4,058.3% during the 1st quarter, Holdings Channel.com reports. The institutional investor owned 57,135 shares of the medical research company’s stock after purchasing an additional 55,761 shares during the quarter. Fifth Third Bancorp’s holdings in Bruker were worth $2,064,000 at the end of the most recent reporting period.

Other large investors have also modified their holdings of the company. Orbis Allan Gray Ltd lifted its stake in Bruker by 5.4% in the 4th quarter. Orbis Allan Gray Ltd now owns 14,906,730 shares of the medical research company’s stock valued at $702,256,000 after buying an additional 761,258 shares in the last quarter. State Street Corp increased its position in Bruker by 2.5% during the fourth quarter. State Street Corp now owns 3,831,814 shares of the medical research company’s stock worth $180,700,000 after buying an additional 91,706 shares in the last quarter. AQR Capital Management LLC raised its holdings in shares of Bruker by 125.3% in the second quarter. AQR Capital Management LLC now owns 3,326,820 shares of the medical research company’s stock worth $137,065,000 after acquiring an additional 1,850,215 shares during the last quarter. Sculptor Capital LP raised its holdings in shares of Bruker by 18.3% in the second quarter. Sculptor Capital LP now owns 3,074,801 shares of the medical research company’s stock worth $126,682,000 after acquiring an additional 476,363 shares during the last quarter. Finally, Price T Rowe Associates Inc. MD lifted its position in shares of Bruker by 2,963.4% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 2,366,520 shares of the medical research company’s stock valued at $111,488,000 after acquiring an additional 2,289,269 shares in the last quarter. 79.52% of the stock is currently owned by institutional investors and hedge funds.

Bruker Price Performance

Bruker stock opened at $60.43 on Wednesday. The company has a quick ratio of 0.72, a current ratio of 1.55 and a debt-to-equity ratio of 0.67. The firm has a market capitalization of $9.20 billion, a P/E ratio of -251.79, a PEG ratio of 1.80 and a beta of 1.29. The firm has a fifty day moving average of $55.29 and a 200-day moving average of $46.03. Bruker Corporation has a 52-week low of $28.53 and a 52-week high of $64.54.

Bruker (NASDAQ:BRKR) last announced its quarterly earnings results on Wednesday, May 6th. The medical research company reported $0.31 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.23 by $0.08. Bruker had a positive return on equity of 11.60% and a negative net margin of 0.65%.The firm had revenue of $823.40 million during the quarter, compared to the consensus estimate of $795.62 million. During the same period in the prior year, the firm earned $0.47 EPS. The firm’s quarterly revenue was up 2.7% compared to the same quarter last year. Bruker has set its FY 2026 guidance at 2.100-2.150 EPS. As a group, analysts predict that Bruker Corporation will post 2.12 EPS for the current year.

Bruker Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Tuesday, July 7th. Investors of record on Monday, June 22nd were issued a dividend of $0.05 per share. This represents a $0.20 annualized dividend and a dividend yield of 0.3%. The ex-dividend date was Monday, June 22nd. Bruker’s dividend payout ratio (DPR) is presently -83.33%.

Wall Street Analysts Forecast Growth

Several research firms have issued reports on BRKR. Citigroup raised their price target on shares of Bruker from $44.00 to $60.00 and gave the stock a “neutral” rating in a research note on Wednesday, July 8th. Weiss Ratings raised shares of Bruker from a “sell (d)” rating to a “sell (d+)” rating in a research note on Wednesday, June 3rd. Guggenheim raised their target price on shares of Bruker from $50.00 to $70.00 and gave the stock a “buy” rating in a research report on Monday, June 29th. TD Cowen reaffirmed a “hold” rating on shares of Bruker in a research note on Wednesday, July 15th. Finally, Barclays boosted their price target on Bruker from $53.00 to $60.00 and gave the company an “overweight” rating in a report on Wednesday, June 24th. One equities research analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, six have assigned a Hold rating and two have assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Hold” and a consensus price target of $56.79.

About Bruker

Bruker Corporation, founded in 1960 by physicist Günther Laukien and headquartered in Billerica, Massachusetts, is a leading developer and manufacturer of high-performance scientific instruments and analytical solutions. The company designs systems that enable molecular and materials research across academic, governmental, and industrial laboratories.

Bruker’s product portfolio encompasses nuclear magnetic resonance (NMR) spectrometers for molecular structure and dynamics studies, mass spectrometry platforms for proteomics and metabolomics, X-ray diffraction and scattering instruments for crystallography and materials characterization, atomic force and scanning probe microscopes for nanoscale surface analysis, as well as preclinical imaging systems such as micro-CT and MRI scanners.

In addition to hardware, Bruker provides software suites, applications support, training services, and long-term maintenance agreements to ensure optimal instrument performance.